camostat mesylate
Camostat is a serine protease inhibitor. Serine protease enzymes have a variety of functions in the body, and so camostat has a diverse range of uses. Camostat is approved in Japan for the treatment of chronic pancreatitis and postoperative reflux esophagitis. The oral proteolytic enzyme inhibitor has been on the market since 1985 under the trade name Foipan Tablets. The manufacturer is Ono Pharmaceutical. The drug is used in the treatment of some forms of cancer and is also effective against some viral infections, as well as inhibiting fibrosis in liver or kidney disease or pancreatitis. — Wikipedia
Clinical trial activity
29 trials · 35 clinical orgs · 0 marketing orgs
Earliest trial started Jul 1, 2007 (NCT00506792)
Timeline
Indications
Approved for
Studied for
- Bleeding Time · Phase 1/Phase 2
- Cardiovascular Diseases · Phase 1/Phase 2
- Chronic Kidney Disease-Mineral and Bone Disorder · Phase 2
- Coronavirus Infections · Phase 2
- COVID-19 · Phase 4
- Cystic Fibrosis · Phase 2
- Diabetes Mellitus · Phase 2
- Drug Therapy · Phase 2
- Fontan Procedure · Phase 2
- Healthy Volunteers · Phase 1
- Hypertension · Phase 2
- Obesity · Phase 2
- Pancreatitis, Chronic · Phase 1/Phase 2
- Protein-Losing Enteropathies · Phase 2
- Severe Acute Respiratory Syndrome · Phase 3
Mechanism of action
- Transmembrane protease serine 2ANTAGONIST
TMPRSS2 antagonist
Chemistry & pharmacology
SMILES
CN(C)C(=O)COC(=O)Cc1ccc(OC(=O)c2ccc(NC(=N)N)cc2)cc1- Mol. weight
- 398.42 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaCamostat ↗
- ChEMBLCHEMBL85164 ↗
- ChEMBLCHEMBL590799 ↗
Also known as
- camostat
- camostat
- camostat
- camostat
- camostat
- camostat mesilate
- camostat mesylate
- ni-03
- qau145
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06794593 | Phase 2 | Nov 21, 2024 | University of Southern Denmark |
| NCT05474664 | Phase 2 | Aug 1, 2022 | Seoul National University |
| NCT04730206 | Phase 3 | Jun 15, 2021 | Free University of Brussels, Ghent University, Katholieke Universiteit Leuven, University of Antwerp, University of Liege |
| NCT04662073 | Phase 2 | Apr 23, 2021 | Stanford University |
| NCT04662086 | Phase 2 | Apr 23, 2021 | Stanford University |
| NCT04782505 | Phase 1 | Mar 13, 2021 | Daewoong Pharmaceutical Co. LTD. |
| NCT04750759 | Phase 2 | Feb 3, 2021 | Bayer, Humboldt University |
| NCT04652765 | Phase 1 | Feb 3, 2021 | Johns Hopkins University |
| NCT04713176 | Phase 3 | Feb 2, 2021 | Daewoong Pharmaceutical Co. LTD. |
| NCT04721535 | Phase 3 | Jan 31, 2021 | Daewoong Pharmaceutical Co. LTD. |
| NCT04681430 | Phase 2 | Dec 26, 2020 | Government of Germany, University of Duesseldorf |
| NCT04608266 | Phase 3 | Dec 3, 2020 | Assistance Publique - Hôpitaux de Paris |
| NCT04524663 | Phase 2 | Nov 30, 2020 | Stanford University |
| NCT04583592 | Phase 2 | Nov 9, 2020 | Sagent Pharmaceuticals, Inc. |
| NCT04657497 | Phase 3 | Nov 9, 2020 | Ono Pharmaceuticals |
| NCT04625114 | Phase 2 | Nov 4, 2020 | Ghent University, Universitair Ziekenhuis Gent |
| NCT04530617 | Phase 2 | Oct 5, 2020 | Hospital General Dr. Manuel Gea Gonzalez, Instituto Nacional de Cardiologia Ignacio Chavez, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, National Autonomous University of Mexico |
| NCT04455815 | Phase 2/Phase 3 (Phase 3) | Sep 25, 2020 | Cancer Research UK, Latus Therapeutics |
| NCT04521296 | Phase 2 | Aug 31, 2020 | Daewoong Pharmaceutical Co. LTD. |
| NCT04435015 | Phase 1/Phase 2 (Phase 2) | Aug 1, 2020 | Ono Pharmaceuticals, Yale University |